Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 8/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | CYP1A1 | P04798 | 6/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 6/20 | 1.00 |
| ▸ | CYP1B1 | Q16678 | 6/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 4/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 1.00 |
| ▸ | CA12 | O43570 | 3/20 | 1.00 |
| ▸ | CA4 | P22748 | 3/20 | 1.00 |
| ▸ | CA7 | P43166 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | SLCO2B1 | O94956 | 2/20 | 1.00 |
| ▸ | PSMB5 | P28074 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | PKM | P14618 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eriodictyol SCHEMBL19180 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 | |
| Eriodictyol SCHEMBL29709569 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 | |
| Eriodictyol SCHEMBL2309591 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 | |
| Eriodictyol SCHEMBL29382523 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 | |
| Eriodictyol SCHEMBL30468822 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 | |
| Eriodictyol SCHEMBL29603762 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 | |
| Eriodictyol SCHEMBL23686074 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 | |
| Naringenin SCHEMBL1048136 | 0.89 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 | |
| Naringenin SCHEMBL20570 | 0.89 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 | |
| Naringenin SCHEMBL20571 | 0.89 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023064318-A1 | BIPHASIC COMPOSITIONS COMPRISING ONE OR BOTH OF CARBONATE AND PHOSPHATE | Natural Extraction Systems, LLC (US) | 2023-04-20 | — | — | WO | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| EP-4642472-A1 | PLANT HYDROETHANOLIC EXTRACTS | O SIGMA CELL AND GENETIC LLC (US) | 2025-11-05 | — | — | EP | disclosed |
| EP-4642471-A1 | PLANT HYDROETHANOLIC EXTRACTS AND USES THEREOF | IMMUNE & GENETICS PROTOCOLS LLC (US) | 2025-11-05 | — | — | EP | disclosed |
| CN-119553002-A | Analysis method of sorghum cadmium stress response | 河北省农林科学院谷子研究所 | 2025-03-04 | — | — | CN | disclosed |
| WO-2024141930-A1 | PLANT HYDROETHANOLIC EXTRACTS AND USES THEREOF | IMMUNE & GENETICS PROTOCOLS LLC (US) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024141931-A1 | PLANT HYDROETHANOLIC EXTRACTS | O SIGMA CELL AND GENETIC LLC (US) | 2024-07-04 | — | — | WO | disclosed |
| EP-4376798-A1 | PRESERVATIVES FOR COSMETIC AND PHARMACEUTICAL COMPOSITIONS | Sachem, Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| CN-117813075-A | Preservative for cosmetic and pharmaceutical compositions | 赛成公司 | 2024-04-02 | — | — | CN | disclosed |
| US-20230416228-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEWYORK | 2023-12-28 | — | — | US | disclosed |
| EP-4217355-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | Forkhead Biotherapeutics, inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2023009849-A1 | PRESERVATIVES FOR COSMETIC AND PHARMACEUTICAL COMPOSITIONS | SACHEM, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| US-11547122-B2 | Preventing physical instability of heat treated dairy based products | ARLA FOODS AMBA (DK) | 2023-01-10 | — | — | US | disclosed |
| CN-114686615-A | Molecular marker of F3' H homologous gene and application thereof | 上海市农业科学院 | 2022-07-01 | — | — | CN | disclosed |
| US-20220194939-A1 | Novel compounds and methods of use treating fructose-related disorders or diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-06-23 | — | — | US | disclosed |
| US-20220185797-A1 | SELECTIVE FOXO INHIBITORS FOR TREATMENT OF DIABETES AND OTHER DISORDERS RELATED TO IMPAIRED PANCREATIC FUNCTION | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2022-06-16 | — | — | US | disclosed |
| WO-2022066938-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | FORKHEAD BIOTHERAPEUTICS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| EP-3965761-A1 | SELECTIVE FOXO INHIBITORS FOR TREATMENT OF DIABETES AND OTHER DISORDERS RELATED TO IMPAIRED PANCREATIC FUNCTION | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-03-16 | — | — | EP | disclosed |
| EP-3955914-A1 | NOVEL COMPOUNDS AND METHODS OF USE TREATING FRUCTOSE-RELATED DISORDERS OR DISEASES | Colorado Research Partners, LLC (US) | 2022-02-23 | — | — | EP | disclosed |
| CN-110616162-B | Pichia pastoris for expressing flavone synthase | 佛山市汇腾生物技术有限公司 | 2022-02-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416228-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | FOXO1, FOXO3, GCKR | CYP19A1 1459/4885CYP3A4 4584/4885CYP1A1 4767/4885 |
| US-20220194939-A1 | Novel compounds and methods of use treating fructose-related disorders or diseases | GCK, KHK, HK1 | CYP19A1 3257/4885CYP3A4 2057/4885CYP1A1 2984/4885 |
| US-20220185797-A1 | SELECTIVE FOXO INHIBITORS FOR TREATMENT OF DIABETES AND OTHER DISORDERS RELATED TO IMPAIRED PANCREATIC FUNCTION | FOXO1, FOXO3, FOXK1 | CYP19A1 786/4885CYP3A4 4683/4885CYP1A1 4697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.